Want to stay informed about our latest developments, products, and services? Please fill out the form below to receive occasional email updates about TriAltus Bioscience and our CL-7 system.
Scientists at Hubei University in China successfully used the CL7/Im7 purification system licensed by TriAltus Bioscience to purify Cas9 and Cas12a CRISPR-associated-proteins from E.coli in a single step with a substantially better yield than that of the conventional, multi-step protocol. Read more.
TriAltus Bioscience Announces Licensing Agreement with UAB and Begins to Commercialize Novel Protein Purification Technology
New method saves time, increases yield and purity, and reduces protein preparation costs TriAltus Bioscience, LLC today announced that it has licensed a novel protein purification platform from The University of Alabama at Birmingham (UAB) and is already working to commercialize the technology. The terms of the agreement were not disclosed.
In The News
Lab Notes Blog
Protein purification is a primary step and the basis for numerous biochemical and biomedical studies. It is particularly crucial for high-resolution structural analysis and industrial protein production, where it has to meet the high-yield, high-purity, and high-activity (HHH) requirement. However, the HHH purification of many proteins or protein complexes remains a difficult, target-dependent, and multistep […]
Select Scientific Publications
Publications in peer-reviewed scientific journals have been vetted by experts in the relevant field. You may find the following articles–written by TriAltus Bioscience co-founder Dr. Dmitry Vassylyev and his team–helpful to your own work.